Philips introduces real-time 3D intracardiac imaging in Europe
Royal Philips has introduced its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter across European markets, bringing advanced real-time cardiac visualisation directly into the heart chambers. The innovative imaging system promises to transform structural heart interventions by eliminating the need for general anaesthesia whilst delivering high-resolution 2D and 3D cardiac anatomy visualisation.
Revolutionary imaging technology addresses clinical challenges
The VeriSight Pro system addresses critical limitations in current cardiac imaging approaches. Traditional transesophageal echocardiography (TEE) procedures require general anaesthesia, additional clinical staff, and extended operating room time. The new 3D ICE technology operates through femoral vein catheter insertion, significantly reducing anaesthetic requirements and Post-Anaesthesia Care Unit (PACU) recovery periods.
“With VeriSight Pro 3D ICE, we now have the ability to see detailed cardiac anatomy from inside the heart in real time,” said Prof. Dr. Jörg Hausleiter from Ludwig-Maximilians-Universität (LMU) Munich, Germany. “This helps streamline our workflows and makes complex procedures more accessible to patients who may not tolerate more invasive imaging approaches.”
Technical specifications and clinical applications
The system features a miniaturised ultrasound probe measuring approximately 3 millimetres in diameter, embedded within a steerable catheter tip. This pioneering design enables navigation through the vascular system into heart chambers, delivering real-time high-quality imaging for structural heart and electrophysiology interventions.
Key technical capabilities include xPlane and iRotate technologies, allowing simultaneous visualisation of dual imaging planes and digital view adjustment without physical catheter repositioning. These features enable precise anatomical assessment and device deployment with reduced imaging complexity.
Clinical applications encompass transcatheter valve repair and replacement procedures, left atrial appendage closure, atrial septal defect repair, and tricuspid valve interventions. The technology particularly benefits patients requiring structural heart disease management who may present contraindications for general anaesthesia.
Integrated ecosystem enhances procedural efficiency
VeriSight Pro integrates seamlessly with Philips’ EPIQ ultrasound systems and the Azurion image-guided therapy platform. Combined with EchoNavigator tools, the comprehensive solution provides end-to-end support for complex cardiac interventions.
“VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience,” said Stacy Beske, Business Leader of Image-Guided Therapy Devices at Philips. “It’s availability in Europe is an important milestone in helping more patients benefit from image-guided, minimally invasive heart procedures, whilst supporting care teams with integrated solutions that adapt to the way they work.”
Clinical education and training initiatives
Philips will demonstrate VeriSight Pro capabilities at EuroPCR 2025 in Paris, featuring physician-led symposiums on advanced imaging in structural heart disease interventions. The programme includes hands-on training with Mentice simulators, developed in collaboration with Edwards Lifesciences, and immersive VR-based clinical protocol training for left atrial appendage occlusion and tricuspid valve procedures.
The regulatory status for European markets follows the system’s established clinical performance in the United States, where VeriSight Pro has demonstrated significant procedural benefits in structural heart interventions.
This technological advancement represents a paradigm shift in intracardiac imaging, offering clinicians enhanced procedural confidence whilst reducing patient burden and healthcare resource utilisation.
- For more information, visit: philips.com/europcr
